enGene Therapeutics Inc. · NASDAQ:ENGN

enGene Therapeutics — Investor Presentation (November 2026)

41 slides from enGene Therapeutics's investor presentation, Nov 12, 2026

  1. Slide 1: Corporate Presentation: Non-Viral Genetic Medicine

    Corporate Presentation Non-Viral Genetic Medicine

  2. Slide 2: Cautionary Statement Regarding Forward-Looking Statements

    Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking state

  3. Slide 3: Unlocking Community Practices: Unique Non-Viral Offering

    Unlocking Community Practices Unique Non-Viral Offering Simple storage and handling designed to support broad community adoption Provides opportunity to redefine community care 75% of the patients are in community practices 4Q 2026 Initiate BLA Filing; 2027 Potential BLA Approval; Detalimogene + Sur

  4. Slide 4: DDX Platform: Unique Non-Viral Gene Therapy Without the Headaches

    DDX Platform: Unique Non-Viral Gene Therapy Without the Headaches First Plasmid Gene Therapy in Development Large Genetic Cargo Redosable Low Cost of Goods/ No Specialized Handling Corporate Presentation November 2026 Detalimogene

  5. Slide 5: Non-Muscle Invasive Bladder Cancer

    Non-Muscle Invasive Bladder Cancer

  6. Slide 6: Non-Muscle Invasive Represents 75%-80% of Bladder Cancer Diagnoses

    Non-Muscle Invasive Represents 75%-80% of Bladder Cancer Diagnoses High-Risk NMIBC Patient Segmentation CIS +/- papillary tumors Papillary tumors only NMIBC = non-muscle invasive bladder cancer, HR = High-risk. Sources: SEER database; Knowles et al., Nat Rev Cancer 15, 25–41 (2015); Isharwal and Kon

  7. Slide 7: High-Risk NMIBC is Slowly Progressing but Highly Recurrent

    High-Risk NMIBC is a Slowly Progressing Disease but Highly Recurrent 20% of NMIBC Patients Progress to Muscle Invasive Bladder Cancer (MIBC) Over 10 Years Treatment paradigm diagram is not comprehensive and acts only as an illustration. Additional Sources: Schneider, Bryan J., et al. J Clin Onc 39.3

  8. Slide 8: ~75% of BCG-Unresponsive NMIBC Treated in Community Urology Practices

    ~75% of BCG-Unresponsive NMIBC Treated in Community Urology Practices Corporate Presentation November 2026 Sources: Quantitative Market Research (2,390 patient claims). “The State of the Urology Workforce and Practice in the United States, 2024” American Urological Association Education and Research

  9. Slide 9: Community Urologists Balance a Range of Needs in Selecting Treatments

    Community Urologists Balance a Range of Needs in Selecting Treatments Sources: Quantitative Market Research (2,390 patient claims), “The State of the Urology Workforce and Practice in the United States, 2024” American Urological Association Education and Research, Inc. Raymond James & Associates “Co

  10. Slide 10: Urology Segment NMIBC Patients

    Urology Segment NMIBC Patients 19% (~3,800) 11% (~2,200) 11% (~2,200) 6% (~1,200) 29% (~5,800) Academic Medical Center 24% (~4,800) Note: Assumes ~20,000 addressable NMIBC BCG-unresponsive patients. Resource-Limited, Workflow-Constrained, Economics-Focused, and Clinical-Excellence all represent urol

  11. Slide 11: Detalimogene Voraplasmid

    Detalimogene Voraplasmid

  12. Slide 12: Detalimogene: Designed for Bladder-Localized Immune Activation

    Detalimogene: Designed for Bladder-Localized Immune Activation Synergistic Stimulation of Specific Innate and Adaptive Immune Responses 1. Gao J, et al, inventors; enGene, Inc., assignee. US patent WO 2013/138930 A1. September 26, 2013. 2. Joshi S, et al. Presented at: 2025 ASCO GU Cancers Symposium

  13. Slide 13: Industrial-Scale Manufacturing With Ease of Handling and Low COGS

    Industrial-Scale Manufacturing With Ease of Handling and Low COGS Note: CDRP = Chemistry, Manufacturing and Controls Development and Readiness Pilot. enGene is one of nine companies awarded CDRP per year. Plasmid DNA Proprietary DDX sugar polymer PEG-PLE Easy to Store and Transport Long storage time

  14. Slide 14: Designed to Streamline Experience for Patients and Urology Practices

    Designed to Streamline Experience for Patients and Urology Practices Designed to be Simpler to Use than BCG for Both Patients and Practices Patients Practice Fewer doses per 12-week cycle than BCG induction No urine bleaching or close contact precautions with loved ones Storage at 2-8°C* Administere

  15. Slide 15: Detalimogene is a Potential Low Burden & Convenient Option for Patients

    Treatment Time Dosing Schedule (First 3 Months) Keytruda Adstiladrin Anktiva + BCG Inlexzo Cretostimogene 60 minutes IVI treatment dwell 30min IV infusion 48hr urine bleaching 60min IVI treatment dwell 25min to 5hr vial thaw 6hr urine bleaching 120min IVI treatment dwell Cystoscope device removal 7

  16. Slide 16: Developed for Logistical and Post-Treatment Protocol Simplicity

    Developed for Logistical and Post-Treatment Protocol Simplicity Non-Viral Gene Therapy Viral Gene Therapy Chemo-Device Combination BCG-Cytokine Combo Therapy Checkpoint Inhibitor No Complex Shipping & Storage      Short Administration/Procedure      No Viral/Bacterium Decontamination or HC

  17. Slide 17: Multiple LEGEND Cohorts Maximize Detalimogene's Potential

    Multiple LEGEND Cohorts Maximize Detalimogene’s Potential Comprehensive IP Portfolio Through at Least 2040 *These additional non-pivotal cohorts of the LEGEND study provide further opportunity to demonstrate the potential use of detalimogene in clinical settings with unmet need. Progress as of Octob

  18. Slide 18: Detalimogene Without Surfactant Pivotal Cohort

    Detalimogene Without Surfactant Pivotal Cohort 1

  19. Slide 19: Pivotal Cohort Study Target Enrollment Achieved

    Pivotal Cohort Study Target Enrollment Achieved Patients: BCG-Unresponsive High-risk NMIBC with CIS Design: Global, single-arm, open label N = 125 (fully enrolled) Dosing1: Year 1: 0.8mg/mL in 50mL IVI at weeks 1,2,5,6 Q3M Year 2-3 (Maintenance): 0.8mg/mL IVI at weeks 1,2 Q3M Primary Endpoint: Any t

  20. Slide 20: LEGEND Pivotal Cohort 1: Baseline Demographics and Disease Characteristics

    LEGEND Pivotal Cohort 1: Baseline Demographics and Disease Characteristics Corporate Presentation November 2026 Characteristics Pivotal Cohort 1 (N=125) Age, years Median (Range) 71.0 (35.0-90.0) Sex, n (%) Female 24 (19%) Male 101 (81%) Race n (%) White 114 (91%) Asian 4 (3%) Black or African Ameri

  21. Slide 21: Primary Endpoint: CR at Any Time in Range of Approved Products

    Detalimogene Without Surfactant Primary Endpoint: CR at Any Time Primary Endpoint in Range of Approved Products Corporate Presentation November 2026 Any Time Complete Response* 56% 91% of CRs occurred at first assessment& 100% of responders were free from progression to ≥T2 disease in the bladder 97

  22. Slide 22: Key Secondary Endpoint: Kaplan-Meier Estimated Duration of Response

    Key Secondary Endpoint: Kaplan-Meier Estimated Duration of Response Durability Trending Toward Approved Products, Assessments Ongoing Corporate Presentation November 2026 Duration of Response ≥ 12 months* (KM) 43% (CI: 30%, 55%) *For durability assessments, 1 year is defined as 358 to 365+ days. Nin

  23. Slide 23: Additional Supportive Data: CR Landmark Months Endpoint

    Additional Supportive Data: CR Landmark 12 months Endpoint Not Included in Approved Product Labels Corporate Presentation November 2026 Endpoint Oct 2026 Apr 2026 Complete Response at 12 months, % (95% CI) 24% CI: 16%, 33% (n=110) 13% CI: 7%, 22% (n=98) Median Follow Up of Responders (Months) 12.0 (

  24. Slide 24: Primary Endpoint 56% CR at Any Time; In Range of Approved Products

    Primary Endpoint 56% CR at Any Time; In Range of Approved Products These data are presented for informational purposes and are not based on any head-to-head or comparator clinical studies. Cross-trial comparisons are inherently limited and may suggest misleading similarities or differences. Accordin

  25. Slide 25: Detalimogene Demonstrated Favorable Safety and Tolerability Profile

    Detalimogene Demonstrated Favorable Safety and Tolerability Profile TRAEs were Generally Mild and Reversible, Consistent with Catheterization Low Dose Interruptions and Discontinuations 4% Dose Interruption (n=5) 1% Discontinuation (n=1) Corporate Presentation November 2026 Participants with events

  26. Slide 26: Trending to Potential Best-in-Class Tolerability for Detalimogene

    Trending to Potential Best-in-Class Tolerability for Detalimogene Investigational Agents based on TRAEs*** Detalimogene n=125 Creto n = 112 Any Grade 59% 63% Serious 2% 1.8% Fatal 0 0 Dose Interruptions 4% Not reported Dose Discontinuations 1% 0 Source Oct 2026 Data Analysis* CG Investor Deck** Appr

  27. Slide 27: Detalimogene With Surfactant: Potential to Enhance Efficacy and Durability

    Detalimogene With Surfactant Potential to Enhance Efficacy and Durability

  28. Slide 28: Goal: Enhance Detalimogene Profile While Maintaining Ease of Use

    Goal: Enhance Detalimogene Profile While Maintaining Differentiated Ease of Use, Tolerability, and Patient Experience Corporate Presentation November 2026 Design for Detalimogene without Surfactant Bladder Rinse Design for Detalimogene + Surfactant Bladder Rinse Simple logistics and administration D

  29. Slide 29: Surfactants Increase Transfection of Gene Therapies

    Surfactants Increase Transfection of Gene Therapies Preclinical Evaluation Before and After Surfactant Incorporation Corporate Presentation November 2026 Cretostimogene1 Adstiladrin3 1: Cretostimogene developed with a pre-wash surfactant, DDM, before administration of drug. 2: Ramesh et al. Molecula

  30. Slide 30: Detalimogene + Surfactant: Broad, Deep Urothelial Nanoparticle Distribution

    Detalimogene + Surfactant: Broad, Deep Urothelial Nanoparticle Distribution Increased Gene Expression >10X and Improved Efficacy in Preclinical Murine Models Detalimogene Only Detalimogene + Surfactant Significant Efficacy Increase deta + surfactant >10× Increase IL-12 expression deta + surfactant C

  31. Slide 31: IL-12 Expression Increases: >9X Magnitude and >50% Distribution

    IL-12 Expression Increases: >9X Magnitude and >50% Distribution Murine Model Findings Validated in Non-Human Primate Model Detalimogene Only Surfactant + Detalimogene Corporate Presentation November 2026 No Pretreatment Detalimogene 60m 5-min Pretreatment Detalimogene 15m Increase Mean hIL-12 expres

  32. Slide 32: Clinical Development of a Surfactant Bladder Rinse: 0.25% Polidocanol

    EG-70 (15’) EG-70 (60’) mIL-12 in Plasma pDNA in Plasma Corporate Presentation November 2026 Clinical Development of a Surfactant Bladder Rinse: 0.25% polidocanol Established Clinical and Safety Profile of Polidocanol: Clinical Use: 1-4% IV sclerosing agent for varicose veins, telangiectasias and he

  33. Slide 33: LEGEND Detalimogene + Polidocanol Surfactant Cohort Study Design

    LEGEND Detalimogene + Polidocanol Surfactant Cohort First Patients Enrolled Study Design Target Population: Patients with BCG-unresponsive HR NMIBC with CIS +/- Papillary Enrollment: Up to 80 patients 1w 2w 3w 4w 5w 6w 7w 8w 9w 10w 11w 12w Corporate Presentation November 2026 50 mL bladder rinse (5

  34. Slide 34: Future Market Dynamics

    Future Market Dynamics

  35. Slide 35: Eligible Patient Pool Exceeds the Annual BCG-Unresponsive Incidence

    Eligible Patient Pool Exceeds the Annual BCG-Unresponsive Incidence Patients will Sequence Therapies Creating a Compounding Effect on the Eligible Pool Note: Interviews n=22 urologists. The rate of patients requiring a 3L/4L therapy could be anywhere from 75% - 35% depending on which therapy they re

  36. Slide 36: NCCN Guideline 2A Dictates Payer Coverage At New Price Point

    NCCN Guideline 2A Dictates Payer Coverage At New Price Point Note: WAC = wholesale acquisition cost. Keytruda®, Adstiladrin®, Anktiva®, Inlexzo® are trademarks of their respective owners. New price point assumes price of ~$650K-$700K/per patient per year. Assume gross-to-net discount of 21% and ther

  37. Slide 37: Sizeable Future Market Opportunity for Detalimogene

    Sizeable Future Market Opportunity for Detalimogene Corporate Presentation November 2026 40 - 75K 25 - 30K 50 - 80K Future Potential Total Addressable Market*of 120K+ High Risk BCG-Unresponsive / Exposed High Risk BCG-Naive Intermediate Risk Total Population 120K+ *Detalimogene pivotal study is for

  38. Slide 38: Segmentation and Value Pillars Inform Field Force Deployment

    Segmentation and Value Pillars Inform Field Force Deployment 11,000 Bladder Cancer Urologists Academic Medical Center Health System / Hospital Clinical Excellence Practices Economics-Focused Practices Workflow-Constrained Practices Resource-Limited Practices 14,600 Practicing Urologists Field Force

  39. Slide 39: Experience Developing and Commercializing Highly Successful Medicines

    Experience Developing and Commercializing Highly Successful Medicines Ron Cooper Chief Executive Officer Chief Executive Officer, Albireo Pharma President, Europe, Bristol Myers Squibb Joan Connelly Chief Technology Officer Chief Technology Officer, Albireo Pharma SVP Technical Operations, Stemline

  40. Slide 40: Detalimogene: Next Gen NMIBC Treatment Designed for Community Use

    Detalimogene: Next Gen NMIBC Treatment Designed for Community Use Large Total Addressable Market Differentiated Total Product Profile Lifecycle Management Near-Term Planned Catalysts NMIBC market forecasted to be >$20B Surfactant Bladder Rinse has Potential to Improve Efficacy, Duration of Response

  41. Slide 41: November 2026

    November 2026

enGene Therapeutics — Investor Presentation (November 2026) on 6ix